CompletedNot Applicable

Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism

United States40 participantsStarted 2006-05

Plain-language summary

To investigate the efficacy and safety of once daily enoxaparin as a "bridge" to warfarin for the outpatient treatment of acute deep venous thrombosis or pulmonary embolism.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Symptomatic acute deep venous thrombosis and/or pulmonary embolism confirmed by venous ultrasound and/or CT scan.
✓. Pulmonary embolism patients with normal right ventricular size on chest CT scan.
✓. Age greater than 18 years
✓. Anticipated discharge within 72 hours of admission
✓. Written informed consent

Exclusion criteria

✕. Pregnancy or intend to become pregnant
✕. Patients requiring ongoing hospitalization \> 72 hours
✕. Hypersensitivity to heparin, pork products or enoxaparin
✕. Creatinine \> 2.0 mg/dl
✕. Recurrent DVT and/or PE with oral anticoagulation
✕. Surgery or medical procedure planned during the study that may pose a significant bleeding risk
✕. Prior history of heparin-induced thrombocytopenia
✕. Inability to participate for follow up appointments and study visits

What they're measuring

Major Bleeding Complication

Timeframe: 30 Days

Recurrent VTE

Timeframe: 30 Days

Death

Timeframe: 30 Days

Trial details

NCT IDNCT00413374

SponsorBrigham and Women's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-04

Results submitted2011-06-22

View on ClinicalTrials.gov More Deep Vein Thrombosis trials